Susan K. Whoriskey
Directeur/Membre du Conseil chez Ratio Therapeutics, Inc.
Profil
Susan K.
Whoriskey is currently a Director at Ratio Therapeutics, Inc. She previously worked as a Vice President-Licensing & Business Development at Momenta Pharmaceuticals, Inc.
Postes actifs de Susan K. Whoriskey
| Sociétés | Poste | Début |
|---|---|---|
Ratio Therapeutics, Inc.
 Ratio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ratio Therapeutics, Inc. is a pharmaceutical company based in the United States. The company is based in Boston, MA. The company's mission is to accelerate the development of next-generation precision radiopharmaceuticals for solid tumors and transform oncology treatment paradigms. The company's fully integrated proprietary R&D platforms, Trillium™ and Macropa™, enable the imaging, discovery, and advancement of novel radiopharmaceuticals that have first/best-in-class delivery, safety, and efficacy properties. Founded by John Babich, Ph.D., and Jack Hoppin, Ph.D., the company employs a growing team of radiopharmaceuticals discovery and development experts with backgrounds in the life science industry. The CEO of the company is Jack William Hoppin. | Directeur/Membre du Conseil | 01/02/2023 |
Anciens postes connus de Susan K. Whoriskey
| Sociétés | Poste | Fin |
|---|---|---|
| MOMENTA PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Momenta Pharmaceuticals, Inc.
 Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
Ratio Therapeutics, Inc.
Ratio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ratio Therapeutics, Inc. is a pharmaceutical company based in the United States. The company is based in Boston, MA. The company's mission is to accelerate the development of next-generation precision radiopharmaceuticals for solid tumors and transform oncology treatment paradigms. The company's fully integrated proprietary R&D platforms, Trillium™ and Macropa™, enable the imaging, discovery, and advancement of novel radiopharmaceuticals that have first/best-in-class delivery, safety, and efficacy properties. Founded by John Babich, Ph.D., and Jack Hoppin, Ph.D., the company employs a growing team of radiopharmaceuticals discovery and development experts with backgrounds in the life science industry. The CEO of the company is Jack William Hoppin. | Health Technology |
